Gilder Gagnon Howe & Co. LLC decreased its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 3.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 899,671 shares of the biotechnology company’s stock after selling 28,611 shares during the period. Sarepta Therapeutics makes up approximately 1.1% of Gilder Gagnon Howe & Co. LLC’s holdings, making the stock its 22nd biggest position. Gilder Gagnon Howe & Co. LLC owned 1.15% of Sarepta Therapeutics worth $144,253,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently made changes to their positions in SRPT. Ameritas Investment Company LLC bought a new position in Sarepta Therapeutics in the 1st quarter worth about $28,000. Steward Partners Investment Advisory LLC boosted its stake in Sarepta Therapeutics by 46.1% in the 1st quarter. Steward Partners Investment Advisory LLC now owns 317 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 100 shares in the last quarter. NWK Group Inc. boosted its stake in Sarepta Therapeutics by 30.0% in the 1st quarter. NWK Group Inc. now owns 325 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 75 shares in the last quarter. Schroder Investment Management Group bought a new position in Sarepta Therapeutics in the 1st quarter worth about $38,000. Finally, CSat Investment Advisory L.P. boosted its stake in Sarepta Therapeutics by 19.7% in the 1st quarter. CSat Investment Advisory L.P. now owns 571 shares of the biotechnology company’s stock worth $56,000 after purchasing an additional 94 shares in the last quarter. Institutional investors own 92.70% of the company’s stock.
Sarepta Therapeutics stock traded down $3.94 during midday trading on Friday, hitting $132.75. The stock had a trading volume of 1,075,208 shares, compared to its average volume of 745,620. Sarepta Therapeutics Inc has a 52-week low of $72.05 and a 52-week high of $175.00. The firm’s fifty day moving average is $154.78 and its two-hundred day moving average is $136.46. The company has a current ratio of 6.93, a quick ratio of 6.42 and a debt-to-equity ratio of 0.74.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($1.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.73) by ($0.20). The business had revenue of $137.36 million during the quarter, compared to analysts’ expectations of $112.36 million. Sarepta Therapeutics had a negative net margin of 117.80% and a negative return on equity of 53.02%. As a group, research analysts predict that Sarepta Therapeutics Inc will post -7.36 earnings per share for the current year.
In related news, Director Hans Lennart Rudolf Wigzell sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $159.00, for a total transaction of $1,590,000.00. Following the completion of the sale, the director now directly owns 23,792 shares in the company, valued at $3,782,928. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David T. Howton sold 105,122 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $170.88, for a total value of $17,963,247.36. Following the sale, the executive vice president now owns 33,151 shares of the company’s stock, valued at $5,664,842.88. The disclosure for this sale can be found here. Insiders sold 146,247 shares of company stock valued at $24,482,622 over the last 90 days. Company insiders own 5.90% of the company’s stock.
A number of equities analysts recently issued reports on SRPT shares. Bank of America dropped their price target on shares of Sarepta Therapeutics from $190.00 to $189.00 and set a “buy” rating on the stock in a research note on Friday, August 21st. Robert W. Baird reissued a “buy” rating and issued a $192.00 target price on shares of Sarepta Therapeutics in a research report on Monday, June 8th. Piper Sandler decreased their target price on Sarepta Therapeutics from $206.00 to $200.00 and set an “overweight” rating for the company in a research report on Tuesday, August 4th. Morgan Stanley boosted their target price on Sarepta Therapeutics from $172.00 to $182.00 and gave the stock an “overweight” rating in a research report on Monday, August 10th. Finally, Nomura reissued a “buy” rating and issued a $230.00 target price on shares of Sarepta Therapeutics in a research report on Sunday, May 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and twenty-three have assigned a buy rating to the company. Sarepta Therapeutics has a consensus rating of “Buy” and a consensus price target of $194.25.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Article: Margin
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.